Clinical Trial Update: A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of nicotinamide with oral tetrahydrouridine and decitabine for high-risk sickle cell disease, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Decitabine (Decitabine)
• Nicotinamide (nicotinamide)
• Tetrahydrouridine (tetrahydrouridine)

Snippet

Sponsor: EpiDestiny, Inc. | Conditions: Sickle Cell Disease | Phase 1 | Status: RECRUITING